CureVac N.V. Aktie News

TÜBINGEN, GERMANY AND BOSTON, MA / ACCESS Newswire / June 24, 2025 / CureVac N.V. (NASDAQ:CVAC), a pioneering multinational biotech company developing a new class of transformative medicines based on messenger RNA (mRNA), today announced the voting results of the Company's Annual General Meeting.

CureVac / NL0015436031

CureVac / NL0015436031

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Das Analysehaus Jefferies hat das Kursziel für die Aktien von Curevac NL0015436031 nach der Übernahmeofferte von Biontec von 7 auf 5 US-Dollar gesenkt und die Papiere von "Buy" auf "Hold" abgestuft.

U.S. equities were mixed and little changed at midday as another key measure of inflation, the Producer Price Index (PPI), came in lower than expected. The S&P 500 and Nasdaq advanced, while the Dow Jones Industrial Average was lower.

Biotech stock CureVac NV (NASDAQ:CVAC) was last seen up 32.2% at $5.37, after news that  BioNTech (BNTX) is acquiring the company in all-stock deal worth $1.25 billion.

BioNTech (NASDAQ:BNTX) announced that it is acquiring CureVac (NASDAQ:CVAC), a fellow German mRNA vaccine developer, in an all-stock deal valued at approximately $1.25 billion. Under the deal terms, each share of CureVac will be exchanged for about $5.46 worth of BioNTech American Depositary Shares (ADSs), representing a premium of around 55% over CureVac's recent trading price.